image
Healthcare - Biotechnology - NASDAQ - US
$ 59.61
-4.03 %
$ 11.5 B
Market Cap
298.05
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one INCY stock under the worst case scenario is HIDDEN Compared to the current market price of 59.6 USD, Incyte Corporation is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one INCY stock under the base case scenario is HIDDEN Compared to the current market price of 59.6 USD, Incyte Corporation is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one INCY stock under the best case scenario is HIDDEN Compared to the current market price of 59.6 USD, Incyte Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart INCY

image
$85.0$85.0$80.0$80.0$75.0$75.0$70.0$70.0$65.0$65.0$60.0$60.0$55.0$55.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
4.24 B REVENUE
14.76%
61.4 M OPERATING INCOME
-90.11%
32.6 M NET INCOME
-94.54%
335 M OPERATING CASH FLOW
-32.46%
158 M INVESTING CASH FLOW
175.85%
-2.02 B FINANCING CASH FLOW
-9991.08%
1.05 B REVENUE
-10.67%
205 M OPERATING INCOME
-31.95%
158 M NET INCOME
-21.37%
266 M OPERATING CASH FLOW
-30.21%
1.1 M INVESTING CASH FLOW
105.11%
-12.7 M FINANCING CASH FLOW
-62.16%
Balance Sheet Incyte Corporation
image
Current Assets 3.24 B
Cash & Short-Term Investments 2.16 B
Receivables 853 M
Other Current Assets 228 M
Non-Current Assets 2.21 B
Long-Term Investments 18.8 M
PP&E 794 M
Other Non-Current Assets 1.39 B
39.64 %15.67 %4.18 %14.59 %25.57 %Total Assets$5.4b
Current Liabilities 1.64 B
Accounts Payable 197 M
Short-Term Debt 0
Other Current Liabilities 1.44 B
Non-Current Liabilities 355 M
Long-Term Debt 0
Other Non-Current Liabilities 355 M
9.89 %72.34 %17.77 %Total Liabilities$2.0b
EFFICIENCY
Earnings Waterfall Incyte Corporation
image
Revenue 4.24 B
Cost Of Revenue 312 M
Gross Profit 3.93 B
Operating Expenses 3.87 B
Operating Income 61.4 M
Other Expenses 28.8 M
Net Income 32.6 M
5b5b4b4b4b4b3b3b3b3b2b2b2b2b1b1b500m500m004b(312m)4b(4b)61m(29m)33mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
92.64% GROSS MARGIN
92.64%
1.45% OPERATING MARGIN
1.45%
0.77% NET MARGIN
0.77%
0.95% ROE
0.95%
0.60% ROA
0.60%
0.17% ROIC
0.17%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Incyte Corporation
image
1b1b800m800m600m600m400m400m200m200m00(200m)(200m)(400m)(400m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 32.6 M
Depreciation & Amortization 89.2 M
Capital Expenditures -86.3 M
Stock-Based Compensation 266 M
Change in Working Capital 0
Others 33 M
Free Cash Flow 249 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Incyte Corporation
image
Wall Street analysts predict an average 1-year price target for INCY of $85.6 , with forecasts ranging from a low of $48 to a high of $200 .
INCY Lowest Price Target Wall Street Target
48 USD -19.48%
INCY Average Price Target Wall Street Target
85.6 USD 43.67%
INCY Highest Price Target Wall Street Target
200 USD 235.51%
Price
Max Price Target
Min Price Target
Average Price Target
200200180180160160140140120120100100808060604040Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Incyte Corporation
image
Sold
0-3 MONTHS
2.42 M USD 2
3-6 MONTHS
1.44 M USD 3
6-9 MONTHS
880 K USD 3
9-12 MONTHS
3.58 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript Incyte Corporation (NASDAQ:INCY ) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Greg Shertzer - Director of Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research and Development Christiana Stamoulis - Executive Vice President and Chief Financial Officer Matteo Trotta - EVP, Head of U.S. Dermatology Mohamed Issa - EVP, Head of U.S. Oncology Steven Stein - Chief Medical Officer Conference Call Participants Michael Schmidt - Guggenheim David Lebowitz - Citi Andrew Barrons - Leerink Partners Tazeen Ahmad - Bank of America Jessica Fye - JPMorgan Chase Marc Frahm - TD Cowen Vikram Purohit - Morgan Stanley Ash Verma - UBS James Shin - Deutsche Bank Salim Syed - Mizuho Securities Gavin Clark-Gartner - Evercore ISI Jay Olson - Oppenheimer Operator Greetings, and welcome to the Incyte's First Quarter 2025 Earnings Conference and Webcast. At this time, all participants are in a listen-only mode. seekingalpha.com - 3 weeks ago
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales. zacks.com - 3 weeks ago
Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 3 weeks ago
Incyte (INCY) Q1 Earnings and Revenues Top Estimates Incyte (INCY) came out with quarterly earnings of $1.16 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.64 per share a year ago. zacks.com - 3 weeks ago
Incyte raises 2025 sales forecast for blood cancer drug after solid quarter Incyte Corp raised its annual sales forecast for its blood cancer treatment Jakafi on Tuesday, after robust sales of the drug helped it beat Wall Street estimates for quarterly results. reuters.com - 3 weeks ago
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs. businesswire.com - 3 weeks ago
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AACR25--Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025. businesswire.com - 3 weeks ago
Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi. zacks.com - 3 weeks ago
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 4 weeks ago
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). businesswire.com - 1 month ago
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. globenewswire.com - 1 month ago
Why Incyte Stock Was Tanking This Week A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (INCY 2.23%) stock over the past few days. The gloom this produced was pushing the biotech's share price down by nearly 11% week to date as of Friday before market open. fool.com - 1 month ago
8. Profile Summary

Incyte Corporation INCY

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 11.5 B
Dividend Yield 0.00%
Description Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Contact 1801 Augustine Cut-Off, Wilmington, DE, 19803 https://www.incyte.com
IPO Date Nov. 4, 1993
Employees 2617
Officers Ms. Christiana Stamoulis M.B.A. Executive Vice President & Chief Financial Officer Mr. Michael James Morrissey Executive Vice President & Head of Global Technical Operations Mr. Ben Strain Head of Investor Relations Mr. Thomas Tray Vice President of Finance, Chief Accounting Officer & Controller Ms. Paula J. Swain Executive Vice President of Human Resources Ms. Sheila A. Denton J.D. Executive Vice President, General Counsel & Corporate Secretary Dr. Pablo J. Cagnoni M.D., Ph.D. President and Head of Research & Development Dr. Steven H. Stein M.D. Executive Vice President & Chief Medical Officer Ms. Pamela M. Murphy Vice President of Investor Relations & Corporate Communications Mr. Herve Hoppenot Chairman, President & Chief Executive Officer